• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

Introduction to 3-(4,4-dimethylcyclohexyl)aniline (CAS No. 478403-64-4)

3-(4,4-dimethylcyclohexyl)aniline, identified by the Chemical Abstracts Service Number (CAS No.) 478403-64-4, is a significant organic compound that has garnered attention in the field of pharmaceutical and chemical research. This compound belongs to the class of aromatic amines, characterized by its structural integration of an aniline moiety with a bulky 4,4-dimethylcyclohexyl side chain. The unique combination of these structural elements imparts distinct chemical properties and functionalities, making it a valuable intermediate in synthetic chemistry and a potential candidate for various applications in medicinal chemistry.

The molecular structure of 3-(4,4-dimethylcyclohexyl)aniline consists of a benzene ring substituted with an amino group (-NH?) at the para position relative to the 4,4-dimethylcyclohexyl group. This configuration results in a sterically hindered molecule, which can influence its reactivity and interactions with biological targets. The presence of the dimethylcyclohexyl group not only enhances the lipophilicity of the compound but also introduces steric hindrance, which can be exploited in drug design to improve metabolic stability and reduce off-target effects.

In recent years, there has been growing interest in 3-(4,4-dimethylcyclohexyl)aniline due to its potential applications in the development of novel pharmaceuticals. The compound's ability to serve as a building block for more complex molecules has made it a focal point in synthetic organic chemistry. Researchers have explored its utility in constructing heterocyclic derivatives, which are known for their broad spectrum of biological activities. For instance, derivatives of this compound have been investigated for their potential roles as kinase inhibitors, anticancer agents, and antimicrobial compounds.

One of the most compelling aspects of 3-(4,4-dimethylcyclohexyl)aniline is its versatility in chemical transformations. The aniline moiety can undergo various functionalization reactions, including acylation, alkylation, and sulfonylation, while the cyclohexyl side chain provides multiple sites for further modifications. This flexibility has enabled chemists to tailor the compound's properties for specific applications. For example, researchers have synthesized analogs of this molecule with enhanced solubility or improved binding affinity by modifying the substituents on the cyclohexyl ring.

The pharmacological potential of 3-(4,4-dimethylcyclohexyl)aniline has been further explored through computational modeling and experimental studies. Computational methods have been employed to predict how this compound might interact with biological targets such as enzymes and receptors. These studies have suggested that modifications to the dimethylcyclohexyl group could optimize binding interactions, leading to more effective drug candidates. Experimental validation of these predictions has involved both in vitro assays and preliminary in vivo studies.

In vitro studies have demonstrated that derivatives of 3-(4,4-dimethylcyclohexyl)aniline exhibit promising activity against various disease-related targets. For instance, certain analogs have shown inhibitory effects on tyrosine kinases, which are implicated in cancer progression. Additionally, these compounds have demonstrated antimicrobial properties against resistant bacterial strains, highlighting their potential as novel therapeutic agents. The structural features of this molecule contribute to its ability to disrupt key biological pathways while maintaining selectivity.

The synthesis of 3-(4,4-dimethylcyclohexyl)aniline represents another area of active research. Chemists have developed efficient synthetic routes that leverage modern catalytic methods and green chemistry principles. These approaches not only improve yield and purity but also minimize waste generation. One particularly notable method involves the use of transition metal-catalyzed cross-coupling reactions to construct the core structure of the molecule efficiently. Such advancements underscore the importance of sustainable practices in pharmaceutical synthesis.

The future prospects for 3-(4,4-dimethylcyclohexyl)aniline are bright, with ongoing research aimed at expanding its applications beyond traditional pharmaceuticals. Interest in this compound extends to materials science, where its unique structural properties make it a candidate for developing new polymers or functional materials. Furthermore, its role as a precursor for specialty chemicals is being explored in industries requiring high-performance materials.

In conclusion,3-(4,4-dimethylcyclohexyl)aniline (CAS No. 478403-64-4) is a multifaceted compound with significant potential across multiple domains of chemistry and medicine. Its structural features enable diverse chemical modifications and biological interactions, making it a valuable asset in drug discovery and material science. As research continues to uncover new applications for this molecule,3-(4,4-dimethylcyclohexyl)aniline is poised to play an increasingly important role in addressing global challenges in health and technology.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)